Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) (NCT06393504)

🧪 Interventions in This Study

• Daridorexant (DRUG)
• Non-orexin receptor antagonist insomnia medication (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Carelon Research — Wilmington, Delaware

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Insomnia Disorder

• Assessing Modified CBTi in Adults With Insomnia Disorder — Pocatello, Idaho
• Optimizing an Integrated Mind and Body Treatment for Insomnia: The SLEEPS Study 2 — San Francisco, California
• Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia — Dothan, Alabama
• Virtual Reality Relaxation for Insomnia — Québec, Quebec
• Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia — Québec, Quebec

Explore by condition: All Insomnia Disorder clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.